/
BDX
$151.00-$4.21 (-2.71%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$43.0B
276M shares
52-week range
$140.11 – $213.08
15% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NYSE
CS
Borrow rate
0.39%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-95.79
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $15.98B | $17.29B | $16.07B | $19.13B | $18.87B | $19.37B | $20.18B | $21.84B |
| Cost of revenue | $8.71B | $9.00B | $9.28B | $10.50B | $10.39B | $11.20B | $11.05B | $11.91B |
| Gross profit | $7.27B | $8.29B | $6.80B | $8.63B | $8.48B | $8.17B | $9.13B | $9.92B |
| Gross margin | 45.5% | 47.9% | 42.3% | 45.1% | 44.9% | 42.2% | 45.2% | 45.4% |
| R&D | $1.00B | $1.06B | $1.04B | $1.28B | $1.26B | $1.24B | $1.19B | $1.26B |
| Operating income | $1.51B | $1.76B | $912.0M | $2.25B | $2.28B | $2.11B | $2.40B | $2.58B |
| EBITDA | $3.86B | $4.07B | $3.06B | $4.39B | $4.41B | $4.40B | $4.82B | $4.96B |
| Net income | $311.0M | $1.23B | $874.0M | $2.09B | $1.78B | $1.48B | $1.71B | $1.68B |
| Net margin | 1.9% | 7.1% | 5.4% | 10.9% | 9.4% | 7.7% | 8.4% | 7.7% |
| EPS (diluted) | 0.60 | 3.89 | 2.71 | 6.85 | 5.88 | 4.94 | 5.86 | 5.83 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $19.2B | $12.59 | $12.26–$12.90 | 8 |
| 2027 | $19.7B | $13.40 | $12.72–$15.51 | 8 |
| 2028 | $20.4B | $14.29 | $14.17–$14.54 | 1 |
| 2029 | $21.1B | $15.41 | $15.28–$15.68 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1287.31
Price
$151.00
Implied upside
+753%
Peer comparison
Becton, Dickinson and Co.
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
www.bd.com- Employees
- 72,000
- IPO / List date
- Sep 25, 1963
- HQ
- FRANKLIN LAKES, NJ
Held by traders on TradeandTell
No one on the platform currently holds BDX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-06-30 | 271,391 | $46.7M |
| Bridgewater Associatesas of 2026-03-31 | 9,496 | $1.5M |
Insider activity (SEC Form 4)
Dividend history
TTM yield · 2.77% ($4.19/share)
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-06-09 | $1.0500 | 2026-06-30 |
| 2026-03-10 | $1.0500 | 2026-03-31 |
| 2025-12-08 | $1.0500 | 2025-12-31 |
| 2025-09-08 | $1.0400 | 2025-09-30 |
| 2025-06-09 | $1.0400 | 2025-06-30 |
| 2025-03-10 | $1.0400 | 2025-03-31 |
| 2024-12-09 | $1.0400 | 2024-12-31 |
| 2024-09-09 | $0.9500 | 2024-09-30 |
| 2024-06-10 | $0.9500 | 2024-06-28 |
| 2024-03-07 | $0.9500 | 2024-03-29 |
Recent trades on TradeandTell
No one on the platform has traded BDX yet.
